search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Fatigue after prophylactic cranial irradiation in stage-I-III small cell lung cancer patients: is there a substrate on functional magnetic resonance imaging of the brain?


- candidate number19637
- NTR NumberNTR4837
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR6-okt-2014
- Secondary IDsNL48269.068.14 / METC 14-2-009 
- Public TitleFatigue after prophylactic cranial irradiation in stage-I-III small cell lung cancer patients: is there a substrate on functional magnetic resonance imaging of the brain?
- Scientific TitleFatigue after prophylactic cranial irradiation in stage-I-III small cell lung cancer patients: is there a substrate on functional magnetic resonance imaging of the brain?
- ACRONYMfatigue, prophylactic cranial irradiation, small cell lung cancer, MRI
- hypothesisCancer related fatigue (CRF) is a common problem in cancer patients. 50-90% of these patients report fatigue, the highest percentage is found in patients treated with chemo- and/or radiotherapy. Before starting cancer treatment, cancer patients already report fatigue and cognitive problems. Symptoms often worsen during and after treatment.
CRF may represent imbalances in inflammatory and inhibitory mechanisms induced by cancer and/or chemo- and radiotherapy. For example, in some studies elevated levels of fatigue have been reported in association with increased serum measurements of pro-inflammatory cytokines like IL-6 and TNF-. The hypothesis is that these cytokines cause alterations in the central nervous system (CNS) promoting fatigue. Recently, researchers started to investigate organic substrate in fatigue using functional and structural magnetic resonance imaging (MRI) of the brain as well in non-oncological as oncological patients. Fatigue was linked with regions of decreased frontal and basal ganglia perfusion. MRI is more sensitive in detecting functional differences than behavioural measurements alone. Prophylactic cranial irradiation (PCI) is standard treatment in small cell lung cancer (SCLC) patients with response or stable disease after first line treatment (chemoradiotherapy in stage I-III, chemotherapy in stage IV). These patients report in the first 3 months after PCI significantly more fatigue than patients who have not had PCI, but there are not many data regarding MRI and PCI. In this pilot study we want to evaluate whether there is a substrate for fatigue on MRI and whether there is a correlation with pro-inflammatory cytokines
- Healt Condition(s) or Problem(s) studiedSmall cell lung cancer (SCLC), MRI, Fatigue, Prophylactic cranial irradiation
- Inclusion criteriaStage I-III SCLC:
- Age >/= 18 years
- stage I-III SCLC pathology proven
- Completed initial treatment with chemoradiotherapy, with at least stable disease (SD)
- WHO PS < 2
- Ability to understand written questionnaires
- Written informed consent

Stage III NSCLC:
- Age > 18 years
- stage I-III NSCLC pathology proven
- Completed treatment with chemoradiotherapy, with at least SD
- WHO PS < 2
- Ability to understand written questionnaires
- Written informed consent

Healthy controls:
- Age >18 years
- WHO PS < 2
- Ability to understand written questionnaires
- Written informed consent
- Exclusion criteria- Prior radiotherapy to the brain
- Claustrophobia
- Pregnancy
- Metal implants or other contraindication for MRI
- Inability to lie supine for 30 minutes time (MRI)
- Antidepressants or steroids for the last two weeks
- Clinically relevant anemia (defined as Hb < 5.5 mmol/l)
- Chronic renal failure (defined as MDRD-eGFR < 30 ml/min/1.73m)
- Liver biochemistry abnormalities (defined as more than two times upper limit of normal)
- Major psychiatric illness requiring intervention in secondary care
- mec approval receivedyes
- multicenter trialno
- randomisedno
- group[default]
- Type2 or more arms, non-randomized
- Studytypeintervention
- planned startdate 1-feb-2015
- planned closingdate1-feb-2016
- Target number of participants46
- InterventionsMRI will be performed approximately one week before PCI and two weeks after PCI. Blood samples will be drawn on the same day as the MRI. Fatigue and quality of life will be measured with questionnaires (MVI-20, EORTC c30, EuroQol-5D) on the same day as the MRI. Screening for depression (HADS), cognitive failure (CFQ) will also be done on the same days. The day of the first MRI also includes a personality test (NEO-FFI).
- Primary outcomeChanges in white matter integrity and bold response after PCI. Differences between SCLC patients and controls for change in white matter integrity and bold response.
- Secondary outcome- Relationship between changes in MRI parameters and changes in MVI-20, EORTC c30, EuroQol-5D , HADS and CFQ
- Relationship between changes in MRI parameters and changes in IL-6, TNF, CRP and leukocytes/differential
- To evaluate whether there are differences on MRI findings/laboratory findings / questionnaires between SCLC patients treated with PCI, NSCLC patients and healthy controls
- Timepoints
- Trial web site
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIES L. Hendriks
- CONTACT for SCIENTIFIC QUERIESMD PhD Anne-Marie C. Dingemans
- Sponsor/Initiator Maastricht University Medical Center (MUMC+)
- Funding
(Source(s) of Monetary or Material Support)
AzM
- Publications
- Brief summaryRationale: Cancer related fatigue (CRF) is a common problem in cancer patients. 50-90% of these patients report fatigue, the highest percentage is found in patients treated with chemo- and/or radiotherapy. Before starting cancer treatment, cancer patients already report fatigue and cognitive problems. Symptoms often worsen during and after treatment.
CRF may represent imbalances in inflammatory and inhibitory mechanisms induced by cancer and/or chemo- and radiotherapy. For example, in some studies elevated levels of fatigue have been reported in association with increased serum measurements of pro-inflammatory cytokines like IL-6 and TNF-. The hypothesis is that these cytokines cause alterations in the central nervous system (CNS) promoting fatigue. Recently, researchers started to investigate organic substrate in fatigue using functional and structural magnetic resonance imaging (MRI) of the brain as well in non-oncological as oncological patients. Fatigue was linked with regions of decreased frontal and basal ganglia perfusion. MRI is more sensitive in detecting functional differences than behavioural measurements alone. Prophylactic cranial irradiation (PCI) is standard treatment in small cell lung cancer (SCLC) patients with response or stable disease after first line treatment (chemoradiotherapy in stage I-III, chemotherapy in stage IV). These patients report in the first 3 months after PCI significantly more fatigue than patients who have not had PCI, but there are not many data regarding MRI and PCI. In this pilot study we want to evaluate whether there is a substrate for fatigue on MRI and whether there is a correlation with pro-inflammatory cytokines.
Objective: To asses the effect of PCI on the brain with functional MRI (fMRI) and diffusion tensor imaging (DTI)-MRI and assess whether there is a correlation with patient-experienced fatigue. Study design: prospective study
Study population: 22 stage I-III SCLC patients who have completed chemoradiation and are eligible for PCI. Control groups: 12 stage III non-small cell lung cancer (NSCLC) patients who have completed chemoradiation, 12 matched (age, gender, smoking status) healthy individuals.
Intervention: MRI will be performed approximately one week before PCI and two weeks after PCI. Blood samples will be drawn on the same day as the MRI. Fatigue and quality of life will be measured with questionnaires (MVI-20, EORTC c30, EuroQol-5D) on the same day as the MRI. Screening for depression (HADS), cognitive failure (CFQ) will also be done on the same days. The day of the first MRI also includes a personality test (NEO-FFI).
Main study parameters/endpoints: Changes in white matter integrity and bold response after PCI. Differences between SCLC patients and controls for change in white matter integrity and bold response. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The MRI-techniques and questionnaires that are used in this study are non-invasive. The risks of a MRI-scan are negligible because it is a magnetic field, does not involve ionizing radiation and does not require contrast agents or anesthesia. The MRI will be performed twice, preferably the same day as when a regular visit to the radiation oncologist is scheduled. Time per MRI is approximately 30 minutes. The MVI-20, EORTC c30 and EuroQol 5D questionnaires are validated in cancer patients, duration per set of questionnaires is approximately 5 minutes. Screening for depression (HADS) and cognitive failure (CFQ) will also be done (duration per questionnaire approximately 5 minutes). These questionnaires will be taken at the same day as the MRI. The first time the questionnaires also include a personality test (NEO-FFI, duration 10 minutes). Blood samples will be withdrawn twice, total amount is 20 ml. There is no direct benefit for the patient. This is a study to evaluate the usefulness of MRI in fatigue after PCI in order to incorporate this assessment in intervention studies.
- Main changes (audit trail)
- RECORD6-okt-2014 - 15-apr-2016


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl